Stocks making the biggest moves midday: Rogers, United Therapeutics, Moderna, FormFactor & more

Midday trading was driven by sharp company-specific moves: Liquidia fell about 25% before a trading halt after a Delaware court found it infringed a United Therapeutics patent, while United Therapeutics rose 15%. Rogers gained 10% after guiding to roughly $3.80 in full-year adjusted EPS versus $3.65 consensus, while Jabil dropped more than 7% despite fiscal Q4 adjusted EPS of $4.40 versus $4.07 expected and revenue of $10.62B versus $9.71B expected. Moderna declined 7% after Citi downgraded it to sell with a price target 60% below its prior close; FormFactor rose 8% on a Deutsche Bank buy initiation tied to rising semiconductor test intensity and Nvidia GPU exposure.

Analysis

The clearest asymmetric setup is UTHR/LQDA: the ruling shifts value from a speculative launch/royalty assumption toward protection of United Therapeutics' high-margin PAH franchise. For LQDA, a patent overhang can impair financing flexibility and commercial-partnership leverage even before any final remedy; for UTHR, the market may still be underpricing the duration of cash-flow protection if injunction risk or delayed competitive entry becomes the base case. Near-term volatility remains high because appellate process, remedy language, and any non-infringing reformulation path matter more than the initial headline.

JBL's negative reaction despite an operational beat is a warning that the market is discounting earnings quality and forward mix, not reported execution. The likely issue is whether AI/data-center manufacturing contribution can offset weaker legacy end markets without diluting margins; this creates a 1-3 month downside risk if sell-side estimates remain too high despite guidance. Conversely, ROG and FORM offer more direct exposure to rising AI hardware complexity, but FORM's valuation will become sensitive to evidence that its second-source position converts into durable share rather than qualification-only revenue.

CNXC's revenue pressure during AI implementation is a potentially investable lag effect: automation can reduce billable headcount faster than it creates higher-value services, leaving 6-18 months of margin and revenue dislocation. MRNA's downside is less about a single downgrade than the absence of a clearly underwritten earnings bridge; without visible non-COVID product contribution, multiple support is vulnerable to continued cash-burn revisions. CALM's miss highlights that egg-price normalization can expose operating-cost volatility, making it a poor defensive consumer-staples substitute until margin recovery is demonstrated.

Key Decisions for Investors

• Initiate a 3-6 month long UTHR / short LQDA pair, sized smaller on the short given binary legal volatility. Target a further 10-15% UTHR rerating if competitive-entry timing extends; cover the pair if LQDA obtains a stay, announces a credible non-infringing product path, or UTHR guidance indicates no material franchise protection.
• Buy FORM on pullbacks rather than chase the initiation-driven move; use a 6-12 month horizon and require confirmation in quarterly probe-card revenue, gross margin, and TSMC/NVDA-related customer concentration disclosures. Risk is qualification fails to translate into production volumes or a GPU-cycle digestion; exit on two consecutive quarters of semiconductor-test order deterioration.
• Treat JBL as a tactical short/watch candidate only after reviewing segment-level fiscal-year margin guidance and backlog conversion. A break in forward EPS estimates would support 10-15% downside over 1-3 months; abandon the thesis if AI-related revenue growth accelerates while consolidated operating-margin guidance rises.
• Avoid adding MRNA exposure until management provides a measurable revenue and cash-flow bridge from its pipeline. For existing longs, use any 1-3 month rally to reduce risk; thesis turns constructive only if non-COVID launch metrics or partnership economics support materially lower cash-burn expectations.
• Monitor CNXC for a long-term turnaround entry, not an immediate long: initiate only after organic-revenue stabilization and evidence that AI-led productivity gains are retained as margin rather than passed through to clients. Until then, favor a short CNXC versus a diversified IT-services basket on a 3-6 month horizon.